Lynx Biosciences is developing technology to predict how multiple myeloma and other blood cancers will respond to drug treatment, with tests designed to select the drug most likely to benefit a patient. Lynx analyzes a patient’s tumor cells alongside their bone-marrow cells, which influence the tumor cells’ susceptibility and resistance to cancer drugs. The assay uses a miniaturized device developed in collaboration with David Beebe in the UW–Madison Department of Biomedical Engineering. Lynx founder Chorom Pak, who has a doctorate in Molecular and Cellular Pharmacology from UW–Madison, adds that the Lynx approach measures tumor cell survival and can potentially be developed alongside any drug. See more here.